ND-L02-s0201 Injection

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

HealthyModerate to Extensive Hepatic Fibrosis (METAVIR F3-4)

Phase 1

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

CompletedNCT01858935

Bristol-Myers SquibbHealthy

Start: 2013-05-31End: 2014-02-28Updated: 2017-05-11

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

CompletedNCT02227459

Bristol-Myers SquibbModerate to Extensive Hepatic Fibrosis (METAVIR F3-4)

Start: 2014-10-31End: 2016-05-31Updated: 2017-05-11

Related Papers

BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial

Hepatology2021-10-0489 citations